Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

ErbB2 Activation of ESX gene expression

Oncogene volume 21, pages 3934–3938 (2002)Cite this article

Abstract

Various members of the Ets multigene family exhibit diverse roles in development, cell differentiation, tissue-specific gene expression and human malignancy. In the search for Ets factors involved in mammary gland development and malignancy, ESX was found to be upregulated in a subset of breast tumours and cell lines. We report the transcriptional regulation of ESX in epithelial breast cancer cells. Transient reporter assays using the ESX promoter show that ESX transcription is regulated by ErbB receptor signalling. In cell lines and in 45 primary ductal breast cancers we show that ESX transcript expression significantly correlates with ErbB2 transcript levels. Moreover, expression of ErbB2 in cells upregulates ESX promoter activity while inhibition of ErbB2 or its downstream signaling pathways decrease both ESX promoter activity and endogenous ESX protein levels. These results indicate that the ESX promoter represents a transcriptional target of ErbB2, and ESX expression may represent a downstream mediator of ErbB2 signaling and ErbB2-induced gene expression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D . 2000 Nat. Genet. 25: 144–146

  • Andreoli JM, Jang SI, Chung E, Coticchia CM, Steinert PM, Markova NG . 1997 Nucleic Acids Res. 25: 4287–4295

  • Brembeck FH, Opitz OG, Libermann TA, Rustgi AK . 2000 Oncogene 19: 1941–1949

  • Chang CH, Scott GK, Baldwin MA, Benz CC . 1999 Oncogene 18: 3682–3695

  • Chang CH, Scott GK, Kuo WL, Xiong X, Suzdaltseva Y, Park JW, Sayre P, Erny K, Collins C, Gray JW, Benz CC . 1997 Oncogene 14: 1617–1622

  • Collins C, Volik S, Kowbel D, Ginzinger D, Ylstra B, Cloutier T, Hawkins T, Predki P, Martin C, Wernick M, Kuo WL, Alberts A, Gray JW . 2001 Genome Res. 11: 1034–1042

  • Godfrey TE, Kim SH, Chavira M, Ruff DW, Warren RS, Gray JW, Jensen RH . 2000 J. Mol. Diagn. 2: 84–91

  • Khwaja A . 1999 Nature 401: 33–34

  • Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE . 2000 Mol. Cell. Biol. 20: 3210–3223

  • Neve R, Chang CH, Scott GK, Wong A, Friis RR, Hynes NE, Benz CC . 1998 FASEB J. 12: 1541–1550

  • Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC . 2001 Biochem. Biophys. Res. Commun. 280: 274–279

  • Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE . 2000 Oncogene 19: 1647–1656

  • Ng AY-N, Waring P, Ristevski S, Wang C, Wilson T, Pritchard M, Hertzog P, Kola I . 2002 Gastroenterology in press

  • Oettgen P, Barcinski M, Boltax J, Stolt P, Akbarali Y, Libermann TA . 1999 Genomics 55: 358–362

  • Rudders S, Gaspar J, Madore R, Voland C, Grall F, Patel A, Pellacani A, Perrella MA, Libermann TA, Oettgen P . 2000 J. Biol. Chem. 17: 17–

  • Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher 3rd FJ, Thor AD, Benz CC . 2000 Oncogene 19: 6490–6502

  • Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast Jr RC, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI . 2001 Cancer Res. 61: 5895–5904

  • Tymms MJ, Ng AY, Thomas RS, Schutte BC, Zhou J, Eyre HJ, Sutherland GR, Seth A, Rosenberg M, Papas T, Debouck C, Kola I . 1997 Oncogene 15: 2449–2462

  • Yoshida N, Yoshida S, Araie M, Handa H, Nabeshima Y . 2000 Mech. Dev. 97: 27–34

Download references

Acknowledgements

RM Neve was supported in part by a fellowship from the Krebsliga beider Basel and the Breast Cancer Fund of the State of California through the Breast Cancer Research Program of the University of California, Grant 7BF-0027. This work was supported in part by NIH sponsored grants P01-CA44768 and R01-CA36773 as well as the Hazel P Munroe and Janet Landfear (Mt. Zion Health Systems) memorial funds.

Author information

Authors and Affiliations

  1. Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, 94945, California, USA

    Richard M Neve, Chuan-Hsiung Chang & Christopher C Benz

  2. Cancer Research Institute, University of California, San Francisco, Box 0808, San Francisco, California, USA

    Bauke Ylstra & Donna G Albertson

Authors
  1. Richard M Neve
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bauke Ylstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chuan-Hsiung Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Donna G Albertson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher C Benz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher C Benz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neve, R., Ylstra, B., Chang, CH. et al. ErbB2 Activation of ESX gene expression. Oncogene 21, 3934–3938 (2002). https://doi.org/10.1038/sj.onc.1205503

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205503

Keywords

This article is cited by

Search

Advanced search

Quick links